VivoSeq
Other

Neoadjuvant Therapy

0

Pipeline Programs↗

62

Active Trials↗

2

Companies Involved↗

Neoadjuvant Therapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Shanghai Henlius Biotech, Roche.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

45/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

0 programs

PreclinicalRoche logo

Roche

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

80

clinical trials

Recruiting30 · 38%
Not yet recruiting26 · 33%
Unknown status9 · 11%
Completed7 · 9%
Active, not recruiting5 · 6%
Withdrawn2 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

80 trials

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC
Recruiting·MMedical University Innsbruck·Phase 2·NCT04875585·33 enrolled
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Recruiting·SSun Yat-sen University·Phase 2·NCT07386158·21 enrolled
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Recruiting·OObstetrics & Gynecology Hospital of Fudan University·Phase 2·NCT06878222·35 enrolled
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05980702·192 enrolled
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06245889·30 enrolled
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
Recruiting·WWest China Hospital·Phase 2·NCT06664996·33 enrolled
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05941338·100 enrolled
Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC
Recruiting·—·N/A·NCT06700382·1,166 enrolled
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Recruiting·—·Phase 2·NCT07492342·30 enrolled
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
Recruiting·TTang-Du Hospital·Phase 2·NCT06006650·114 enrolled
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
Recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06775275·60 enrolled
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Recruiting·YYale University·Phase 1·NCT05989347·20 enrolled
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06992336·411 enrolled
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Recruiting·—·Phase 2·NCT06420440·160 enrolled
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429463·250 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)